PROGNOSTIC BIOMARKERS IN TRIPLE NEGATIVE BREAST CANCER AS A POTENTIAL TARGET FOR FUTURE DRUG DISCOVERY

Breast cancer is the most common malignancy in women globally, in which triple-negative breast cancer (TNBC) is more aggressive with poor prognosis and very less response to targeted hormone based treatment. It is a major cause of deaths among the women with breast cancer because of very few treatment options. The biomarkers could be a product of cancerous cell or molecule generated in response to cancer. It is used to understand the mechanism, prognosis, diagnosis as well as target for design and discovery of new drugs. The purpose of the study is to give a brief review onmarkers of TNBC